|Bid||123.42 x 900|
|Ask||123.47 x 900|
|Day's Range||123.27 - 128.39|
|52 Week Range||80.24 - 140.36|
|Beta (3Y Monthly)||0.69|
|PE Ratio (TTM)||132.66|
|Earnings Date||Nov 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||146.17|
Blood management firm Haemonetics is pulling back to a support level, which could potentially provide investors with a new buying opportunity.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of June 28. In this […]
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Today we are going to look at Haemonetics Corporation (NYSE:HAE) to see whether it might be an attractive investment...
BRAINTREE, Mass. , Sept. 17, 2019 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2020 financial results at 6:00 am EDT on Friday, ...
BRAINTREE, Mass. , Sept. 12, 2019 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient ...
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.